| 1. |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J National Cancer Center, 2022, 2(1): 1-9.
|
| 2. |
曾勇, 謝坤林. 肝癌全程管理模式. 中國實用外科雜志, 2021, 41(3): 343-347.
|
| 3. |
四川大學華西醫院肝癌MDT團隊. 肝細胞肝癌全程多學科規范化管理: 華西醫院多學科專家共識 (第二版). 中國普外基礎與臨床雜志, 2020, 27(9): 1062-1077.
|
| 4. |
Vietti Violi N, Gnerre J, Law A, et al. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. Eur Radiol, 2022, 32(9): 6493-6503.
|
| 5. |
Yoon J, Lee S, Shin J, et al. LI-RADS version 2018 treatment response algorithm: diagnostic performance after transarterial radioembolization for hepatocellular carcinoma. Korean J Radiol, 2021, 22(8): 1279-1288.
|
| 6. |
中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范(2019年版). 中華消化外科雜志, 2020, 19(1): 1-20.
|
| 7. |
中國抗癌協會肝癌專業委員會轉化治療協作組. 肝癌轉化治療中國專家共識 (2021版). 中華消化外科雜志, 2021, 20(6): 600-616.
|
| 8. |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol, 2019, 37(24): 2141-2151.
|
| 9. |
Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol, 2020, 21(7): 947-956.
|
| 10. |
Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends, 2021, 15(3): 155-160.
|
| 11. |
張曉赟, 朱心睿, 彭偉, 等. 經肝動脈化療栓塞+侖伐替尼+PD-1單抗在中晚期不可切除肝癌轉化切除中的安全性和有效性的前瞻性隊列研究: 初步報告. 中國普外基礎與臨床雜志, 2022, 29(1): 39-45.
|
| 12. |
Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
|
| 13. |
Qu WF, Ding ZB, Qu XD, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open, 2022, 6(5): zrac114. doi: 10.1093/bjsopen/zrac114.
|
| 14. |
Song T, Lang M, Ren S, et al. The past, present and future of conversion therapy for liver cancer. Am J Cancer Res, 2021, 11(10): 4711-4724.
|
| 15. |
中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療指南 (2022年版). 中華消化外科雜志, 2022, 21(2): 143-168.
|
| 16. |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
|
| 17. |
Huang L, Li GM, Zhu JY, et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. Onco Targets Ther, 2012, 5: 457-462.
|
| 18. |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs, 2011, 29(6): 1360-1369.
|
| 19. |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2015, 16(13): 1344-1354.
|
| 20. |
Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant, 2018, 32(5): e13246. doi: 10.1111/ctr.13246.
|
| 21. |
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol, 2013, 59(6): 1193-1199.
|
| 22. |
Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg, 2020, 272(5): 855-862.
|
| 23. |
Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl, 2012, 18(1): 62-69.
|